REGENXBIO Is Maintained at Neutral by Goldman Sachs
Regenxbio Analyst Ratings
Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $12
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $25
RBC Cuts Price Target on REGENXBIO to $25 From $30, Keeps Outperform, Speculative Risk
Clear Street Initiates Regenxbio(RGNX.US) With Buy Rating, Announces Target Price $50
RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $34
Optimistic Buy Rating for RegenXBio Driven by Promising RGX-202 Developments in DMD Treatment
Analysts Are Neutral on These Healthcare Stocks: Medtronic (MDT), RegenXBio (RGNX)
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital
REGENXBIO Is Maintained at Buy by Chardan Capital
Regenxbio Analyst Ratings
Baird Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $39
Raymond James Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $29
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $24
RegenXBio's Promising Market Position and RGX-202's Differentiated Safety Drive Buy Rating
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
Barclays Keeps Their Buy Rating on RegenXBio (RGNX)